Shen Yin

1.6k total citations · 1 hit paper
34 papers, 1.1k citations indexed

About

Shen Yin is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Shen Yin has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Immunology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Shen Yin's work include CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Shen Yin is often cited by papers focused on CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Shen Yin collaborates with scholars based in United States, Canada and Australia. Shen Yin's co-authors include Michael C. Wei, Nancy L. Bartlett, Sarit Assouline, Lihua E. Budde, Jayne C. Boyer, J. Carl Barrett, Asad Umar, Michael Kane, John I. Risinger and Thomas A. Kunkel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shen Yin

30 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shen Yin United States	14	705	631	233	224	195	34	1.1k
Oliver Weigert Germany	20	657 0.9×	788 1.2×	403 1.7×	75 0.3×	178 0.9×	74	1.3k
Amanda Copeland United States	15	623 0.9×	558 0.9×	536 2.3×	117 0.5×	166 0.9×	36	1.2k
Manali Kamdar United States	17	1.1k 1.5×	818 1.3×	149 0.6×	157 0.7×	211 1.1×	90	1.4k
Pau Abrisqueta Spain	22	636 0.9×	1.0k 1.7×	402 1.7×	111 0.5×	421 2.2×	124	1.8k
Brent Tan United States	10	586 0.8×	222 0.4×	365 1.6×	86 0.4×	780 4.0×	26	1.4k
Genevive Hernandez United States	12	624 0.9×	241 0.4×	180 0.8×	121 0.5×	193 1.0×	26	752
Enkhtsetseg Purev United States	21	755 1.1×	225 0.4×	768 3.3×	129 0.6×	308 1.6×	55	1.6k
Javier Muñoz United States	23	1.2k 1.7×	886 1.4×	357 1.5×	90 0.4×	333 1.7×	133	1.8k
Laura Casorzo Italy	19	665 0.9×	144 0.2×	300 1.3×	175 0.8×	160 0.8×	29	1.2k

Countries citing papers authored by Shen Yin

Since Specialization

Citations

This map shows the geographic impact of Shen Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shen Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shen Yin more than expected).

Fields of papers citing papers by Shen Yin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shen Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shen Yin. The network helps show where Shen Yin may publish in the future.

Co-authorship network of co-authors of Shen Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Shen Yin. A scholar is included among the top collaborators of Shen Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shen Yin. Shen Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yin, Shen, et al.. (2025). Prospective observational study of oxidative stress in the pathology of benign prostatic hyperplasia with bladder diverticulum. PLoS ONE. 20(5). e0323677–e0323677. 1 indexed citations

Wang, Xiaoyong, Tarec Christoffer El‐Galaly, Lale Kostakoglu, et al.. (2024). Automated Lugano Metabolic Response Assessment in ¹⁸ F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on ¹⁸ F-Fluorodeoxyglucose–Positron Emission Tomography. Journal of Clinical Oncology. 42(25). 2966–2977. 6 indexed citations

Budde, Lihua E., Sarit Assouline, Laurie H. Sehn, et al.. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 42(19). 2250–2256. 34 indexed citations

Budde, Lihua E., Matthew J. Matasar, Laurie H. Sehn, et al.. (2024). Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1646–1646. 4 indexed citations

Chong, Elise A., Elicia Penuel, Lihua E. Budde, et al.. (2024). Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Advances. 9(4). 696–703. 5 indexed citations

Li, Chi‐Chung, Kapil Gadkar, Genevive Hernandez, et al.. (2023). Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clinical and Translational Science. 16(7). 1134–1148. 44 indexed citations

Schuster, Stephen J., Ling‐Yuh Huw, Christopher R. Bolen, et al.. (2023). Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 143(9). 822–832. 34 indexed citations

Cheah, Chan Y., Nancy L. Bartlett, Sarit Assouline, et al.. (2023). IBCL-489 Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 23. S455–S455.

Yin, Shen, et al.. (2023). Analysis of prognostic factors for vocal fold leukoplakia based on 344 cases at a two-year follow up. The Journal of Laryngology & Otology. 137(10). 1170–1175. 1 indexed citations

10.

Nelson, Jonas A., Saïd C. Azoury, Meghana G. Shamsunder, et al.. (2023). Breast Surgical Oncology Epidemiologic Research: A Guide and Comparison of Four National Databases. Annals of Surgical Oncology. 30(4). 2069–2084. 5 indexed citations

11.

Chong, Elise A., Elicia Penuel, Nancy L. Bartlett, et al.. (2023). Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts. Blood. 142(Supplement 1). 1752–1752.

12.

Shamsunder, Meghana G., et al.. (2022). Propensity Scoring in Plastic Surgery Research: An Analysis and Best Practice Guide. Plastic & Reconstructive Surgery Global Open. 10(2). e4003–e4003. 8 indexed citations

13.

Budde, Lihua E., Laurie H. Sehn, Matthew J. Matasar, et al.. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. The Lancet Oncology. 23(8). 1055–1065. 244 indexed citations breakdown →

14.

Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations

15.

Dong, Wen, et al.. (2019). Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells. SHILAP Revista de lepidopterología. 1 indexed citations

16.

Hernandez, Genevive, Ling‐Yuh Huw, Anton Belousov, et al.. (2019). Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 1585–1585. 11 indexed citations

17.

Budde, Lihua E., Laurie H. Sehn, Sarit Assouline, et al.. (2018). Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. Blood. 132(Supplement 1). 399–399. 44 indexed citations

18.

Kallinteris, Nikoletta L., Leora Horn, Min Tang, et al.. (2017). Abstract CT159: IFN-γ analysis in blood and tissue as a potential prognostic and/or predictive biomarker. Cancer Research. 77(13_Supplement). CT159–CT159. 2 indexed citations

19.

Freimark, Bruce, Jian Gong, Dan Ye, et al.. (2016). Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. Cancer Immunology Research. 4(6). 531–540. 21 indexed citations

20.

Chen, Xiaolan, Yuyin Xu, Li Chen, Guilan Wang, & Shen Yin. (2015). TLR3 Plays Significant Roles against HBV-Associated HCC. Gastroenterology Research and Practice. 2015. 1–9. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact